Amneal Pharmaceuticals, Inc. (AMRX) Wins EU Approval for Adcomfo Biosimilar

Amneal Pharmaceuticals (AMRX) received EU approval for Adcomfo, a biosimilar to XOLAIR. The drug met primary efficacy and safety endpoints in a 600-patient study. Amneal acquired the biosimilar program from Kashiv in 2026. ADVANZ PHARMA holds European commercialization rights. FDA decision on U.S. application is pending.

Original reporting
Published Nov 17, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amneal Pharmaceuticals, Inc. (AMRX) Wins EU Approval for Adcomfo Biosimilar — source image
Decision brief

The 30-second read

$AMRXBullishMed
01

Why it matters

Regulatory approval reduces a key execution risk for the Adcomfo biosimilar and can improve the probability-weighted value of the program, but the article does not provide US FDA timing or financial impact.

02

Market read

A concrete EU regulatory milestone for AMRX’s biosimilar program, with confirmatory-study results, is a tradable de-risking event.

03

What to watch

The article does not quantify expected EU uptake, pricing, or launch date; commercialization rights are held by ADVANZ PHARMA, which can dilute how much AMRX captures near-term economics.

Relevance 8/10Novelty 8/10Timing: post-market, dated 2026-11-17

Background

The EC authorization follows an EMA committee opinion in September and UK authorization in March, and the program is described as acquired with Kashiv in August 2026.

Company-level read

Ticker impact

$AMRXBullishMedium confidence
Context

Amneal (AMRX) received European Commission marketing authorization for its Adcomfo (omalizumab) biosimilar, with a 600-patient confirmatory study meeting efficacy and safety endpoints.

Expected impact

Likely upward bias as the market prices in reduced regulatory risk and improved commercialization prospects for the biosimilar program.

Evidence & confidence

The article is a direct regulatory milestone (EC marketing authorization) with specific confirmatory-study details, but it does not provide financial guidance, launch timing, or sales traction.

Market effects

Supports broader biosimilar sentiment in Europe by signaling continued regulatory acceptance of monoclonal antibody biosimilars.

Positive for EU biosimilar commercialization outlook, potentially affecting competitive dynamics versus originators and other biosimilar entrants.

May modestly influence global expectations for Amneal’s pipeline progress, but the article notes the larger catalyst would be FDA action in the US.

Counterpoint

EU approval may already be partially anticipated by the market given prior EMA committee opinion and UK authorization, limiting incremental upside until launch and sales data arrive.

Key entities

  • Amneal Pharmaceuticals, Inc.

    Subject of the article, granted EU marketing authorization for Adcomfo (omalizumab) biosimilar.

  • European Commission

    Granted marketing authorization for Adcomfo in the EU.

  • ADVANZ PHARMA

    Holds European commercialization rights per the article.

  • XOLAIR

    Originator product to which Adcomfo is compared for biosimilarity.

Related articles

$AMRXMedAI 8/10

Amneal receives EU approval for omalizumab biosimilar

Amneal Pharmaceuticals (AMRX) received EU approval for Adcomfo, a biosimilar to XOLAIR. The approval covers treatments for severe allergic asthma, chronic rhinosinusitis, and chronic urticaria. Adcomfo was developed by Kashiv BioSciences, acquired by Amneal in August. The product is supported by clinical data and is marketed in Europe by ADVANZ PHARMA. AMRX's U.S. application is under FDA review.

$AMRXHighAI 8/10

Amneal Earnings Call Signals Strong Growth Ahead

Amneal Pharmaceuticals (AMRX) reported Q3 revenue of $863M, up 10% YoY, with adjusted EBITDA rising 30% to $207M and adjusted EPS increasing 53% to $0.26. The company raised its 2026 revenue outlook to $3.15B-$3.25B and adjusted EBITDA guidance to $800M-$815M. Growth was driven by specialty brands, the Kashiv acquisition, and biosimilar platforms, though management noted pressure from AvKARE and temporarily higher leverage.

$AMRXMed

Piper Sandler reiterates Amneal stock rating on earnings beat

Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.